antibody

Cytochrome P450 1A2

MBS395073

0.2 mg

340 USD

monoclonal

mouse

nonconjugated

[3B8C1]

human, rat

Antibody

Cytochrome P450 1A2

[Cytochrome P450 1A2]

[CYPIA2; P450-P3; P(3)450; P450 4]

[cytochrome P450 1A2; Cytochrome P450 1A2; cytochrome P450 1A2; CYPIA2; P450 form 4; cytochrome P450 4; cytochrome P(3)450; cytochrome P450-P3; dioxin-inducible P3-450; microsomal monooxygenase; xenobiotic monooxygenase; aryl hydrocarbon hydroxylase; flavoprotein-linked monooxygenase; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; cytochrome P450, family 1, subfamily A, polypeptide 2; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3]

[CYP1A2; CYP1A2; CP12; P3-450; P450(PA)]

CP1A2_HUMAN

Monoclonal

IgG1

[3B8C1]

Mouse

Human, Rat.

516

Protein A/G Chromatography

Unconjugated. Provided as solution in phosphate buffered saline with 0.08% sodium azide

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles. Shipping conditions: Ship at ambient temperature, freeze upon arrival.

Western Blotting (WB)

Antibody can be used for Western blotting (1-2 ug/mL) and immunohistochemistry (1-5 ug/mL). Optimal concentration should be evaluated by serial dilutions.

Immunohistochemistry (IHC)

Immunogen: Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with rat cytochrome p450 proteins and mouse myeloma Ag8563 cells.

Positive Control: Normal human liver sections

Monoclonal Antibody

P450 enzymes constitute a family of monooxygenase enzymes that are involved in the metabolism of a wide array of endogenous and xenobiotic compounds. Several P450 enzymes have been classified by sequence similarities as members of the CYP1A and CYP2A subfamilies. NADPH cytochrome 450 reductase is a microsomal enzyme responsible for the transfer of electrons from NADPH to cytochrome P450 enzymes during the P450 catalytic cycle. NADPH cytochrome P450 reductase is localized to the endoplasmic reticulum where it is also able to transfer electrons to heme oxygenase and cytochrome 5. NADPH cytochrome P450 reductase is structurally related to two separate flavoprotein families, ferredoxin nucleotide reductase (FNR) and flavodoxin. Electron transfer of NADPH cytochrome P450 reductase requires the binding of two flavin cofactors, FAD and FMN, to the FNR and flavodoxin domains, respectively.

73915100

NP_000752.2

NM_000761.3

P05177

Aflatoxin B1 Metabolism Pathway (198808); AhR Pathway (755436); Arachidonic Acid Metabolism Pathway (685553); Aromatic Amines Can Be N-hydroxylated Or N-dealkylated By CYP1A2 Pathway (105704); Arylamine Metabolism Pathway (198830); Biological Oxidations Pathway (105698); Caffeine Metabolism Pathway (82945); Caffeine Metabolism Pathway (308); Chemical Carcinogenesis Pathway (673221); Chemical Carcinogenesis Pathway (673237)

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The protein encoded by this gene localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke. The enzyme's endogenous substrate is unknown; however, it is able to metabolize some PAHs to carcinogenic intermediates. Other xenobiotic substrates for this enzyme include caffeine, aflatoxin B1, and acetaminophen. The transcript from this gene contains four Alu sequences flanked by direct repeats in the 3' untranslated region. [provided by RefSeq, Jul 2008]

Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin. Ref.11. Catalytic activity: RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O. Cofactor: Heme group. Subcellular location: Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein. Tissue specificity: Liver. Induction: By nicotine, omeprazole, phenobarbital, primidone and rifampicin. Polymorphism: The CYP1A2*1F allele which is quite common (40 to 50%) is due to a substitution of a base in the non-coding region of the CYP1A2 gene and has the effect of decreasing the enzyme inducibility. Individuals who are homozygous for the CYP1A2*1F allele are 'slow' caffeine metabolizers. Thus for these individual increased intake of caffeine seems to be associated with a concomitant increase in the risk of non-fatal myocardial infraction (MI). Sequence similarities: Belongs to the cytochrome P450 family. Biophysicochemical propertiesKinetic parameters:KM=4 uM for 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole Ref.11KM=21 uM for 2-amino-3-methylimidazo[4,5-f]quinolineKM=26 uM for 2-amino-2,4-dimethylimidazo[4,5-f]quinolineKM=27 uM for 2-amino-3,8-dimethylimidazo[4,5-f]quinoxalineKM=71 uM for 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridineKM=25 uM for phenacetin

0.2 mg

340 USD